Key Points
- BeOne Medicines SVP Chan Henry Lee sold 1,044 shares at an average price of $323.69, totaling $337,932.36. The transaction was made to cover tax withholding obligations tied to vested equity awards, following several earlier sales.
- ONC shares opened at $313.77, with a market capitalization of approximately $34.43 billion and a P/E ratio of 70.19. The company recently reported quarterly revenue of $1.51 billion and EPS of $0.25.
- Wall Street remains broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $394. Institutional investors and hedge funds own approximately 48.55% of the company.
BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) SVP Chan Henry Lee sold 1,044 shares of the stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $323.69, for a total value of $337,932.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Chan Henry Lee also recently made the following trade(s):
- On Wednesday, July 8th, Chan Henry Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $302.46, for a total value of $200,833.44.
- On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The stock was sold at an average price of $265.98, for a total value of $156,928.20.
- On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total value of $110,265.64.
- On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.
- On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total value of $103,159.04.
BeOne Medicines Stock Down 0.7%
ONC stock opened at $313.77 on Tuesday. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. The firm has a 50 day simple moving average of $293.57 and a 200-day simple moving average of $308.92. The company has a market capitalization of $34.43 billion, a P/E ratio of 70.19 and a beta of 0.49. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. On average, equities research analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post 5.93 earnings per share for the current fiscal year.
Institutional Investors Weigh In On BeOne Medicines
Several institutional investors and hedge funds have recently bought and sold shares of ONC. Mariner LLC lifted its position in BeOne Medicines by 3.8% in the 4th quarter. Mariner LLC now owns 883 shares of the company's stock valued at $269,000 after purchasing an additional 32 shares during the last quarter. Signaturefd LLC boosted its stake in BeOne Medicines by 10.7% during the 4th quarter. Signaturefd LLC now owns 340 shares of the company's stock valued at $103,000 after purchasing an additional 33 shares during the period. Farther Finance Advisors LLC grew its position in BeOne Medicines by 21.8% in the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company's stock worth $66,000 after purchasing an additional 39 shares during the last quarter. CWM LLC grew its position in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Steadtrust LLC grew its position in BeOne Medicines by 3.7% in the 2nd quarter. Steadtrust LLC now owns 1,400 shares of the company's stock worth $399,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have recently weighed in on ONC. Nomura raised shares of BeOne Medicines to a "strong-buy" rating in a research report on Monday, July 27th. Morgan Stanley reiterated an "overweight" rating and issued a $395.00 price target on shares of BeOne Medicines in a research note on Thursday, May 7th. Barclays cut their price objective on BeOne Medicines from $409.00 to $403.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 14th. Citizens Jmp reaffirmed a "market outperform" rating and set a $396.00 target price on shares of BeOne Medicines in a report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. lifted their target price on BeOne Medicines from $415.00 to $425.00 and gave the stock an "overweight" rating in a research report on Thursday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BeOne Medicines currently has a consensus rating of "Moderate Buy" and a consensus price target of $394.00.
View Our Latest Stock Report on ONC
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
